{'fraction_non_alphanumeric': 0.017582417582417582, 'fraction_numerical': 0.004395604395604396, 'mean_word_length': 5.514285714285714, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The case for licensing cytosine now for smoking cessation is overwhelming

Prochaska and colleagues’ excellent overview of cytisine in smoking cessation fails to highlight the compelling cost-benefit evidence on why this effective, safe, and inexpensive drug should be licensed immediately worldwide.1 This case has already been made,2 and readers interested in this drug and the inflexibility of Western regulatory systems are directed to this article. …